Fable
5 known investors
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.
Founders & leadership
GM
Geoff MacKayPresident & CEO
DB
David BakerChief Scientific Officer
RW
Rhonda WidemanChief Business Officer
ZM
Zack McNealyChief Financial Officer
Investors · 5
Competitors · 2
by search overlapApplied Therapeutics11 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Mission BioCapital Platinum Program Holdings LLC10 shared keywordsMission BioCapital is an early-stage venture capital firm that provides capital and shared lab space to life science startups, supporting founders from initial experiments through to the clinic. Founded in 2009, it invests in early-stage life science companies and is currently deploying its fifth fund.
Companies competing with Fable for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Claude Fable 5 Free Until July 12: The Fundraising Playbook for Founders (2026)thevccorner.com · Jul 2026Frequently asked questions
- What does Fable do?
- Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.
- Who are Fable's investors?
- Fable's investors include MPM BioImpact, DCVC Bio, Lilly Asia Ventures, Versant Ventures, DCVC (Data Collective).